ModifiedBlue Cross Blue Shield - TexasPolicy CPCPLAB020

Cardiovascular Disease Risk Assessment

Defines Blue Cross Blue Shield Texas reimbursement stance for laboratory tests used in cardiovascular disease (CVD) risk assessment and when such tests may be reimbursable for plan members and providers.

Policy Summary

PayerBlue Cross Blue Shield - Texas

PolicyCardiovascular Disease Risk Assessment

Policy CodePolicy CPCPLAB020

Change TypeRevised testing frequencyclarified reimbursable usescoding updates

Effective DateNov 7, 2025

Next Review DateN/A

Key ActionSubmit documentation showing hs-CRP was used to resolve an uncertain treatment decision after PCE risk assessment when requesting reimbursement.

SourceLink

POLICY UPDATE CHANGES

Revised frequency of hs-CRP testing and added criteria allowing annual screening for confirmed elevated hs-CRP.

Clarified non-reimbursable CRP testing: hs-CRP testing not reimbursable for CVD risk assessments outside specified indications and conventional CRP is not reimbursable for CVD risk assessment.

Added CPT/PLA code 84512 and molecular code 0541U and removed 0423T in reimbursement coding updates.

Specified that testing for uncertain treatment decisions may include hs-CRP after quantitative risk assessment with ACC/AHA PCEs.

18-79recommended lipid screening interval every 4 years

Annuallipid panel frequency for increased CVD risk

Not reimbursableLp(a) adjunct to LDL

Policy Summary

PayerBlue Cross Blue Shield - Texas

PolicyCardiovascular Disease Risk Assessment

Policy CodePolicy CPCPLAB020

Change TypeRevised testing frequencyclarified reimbursable usescoding updates

Effective DateNov 7, 2025

Next Review DateN/A

Key ActionSubmit documentation showing hs-CRP was used to resolve an uncertain treatment decision after PCE risk assessment when requesting reimbursement.

SourceLink

On This Page

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Not reimbursablehs-cTnT outpatient use

2 addedhs-CRP coding entries

3policy update history entries

Coverage criteria for CVD risk assessment tests

Coverage criteria for specific tests

Criteria describing when specific tests are reimbursable or not reimbursable for cardiovascular disease (CVD) risk assessment.

ALL of the following

ANY of the following
- Ages 18 to 79: every 4 years
- Individuals at increased CVD risk (per 2013 ACC/AHA PCEs): annually
ALL of the following
- Obesity or metabolic syndrome
- Nephrotic syndrome
- Hypothyroidism
- Hyperthyroidism
- Pancreatitis
- Diabetes
- Chronic kidney disease
- Cushing Syndrome
- Pregnancy
- Cholestatic liver disease
- Lipid metabolism disorders (e.g., Gaucher disease in adults)
ALL of the following
- Baseline before initiating statin therapy
- Every 4–12 weeks after initiation or change of therapy
- Annually when stable with no medication changes
ALL of the following
- Examples: isotretinoin, antipsychotics
ALL of the following
- Baseline before initiating ART
- Every 1–3 months after initiation or change of therapy
- Every 6–12 months when stable

ALL of the following

ANY of the following
- Hypertriglyceridemia
- Diabetes mellitus
- Obesity or metabolic syndrome
- Other dyslipidemias (e.g., very low LDL-C)
- Individuals on lipid therapy
- Suspected familial dysbetalipoproteinemia or familial combined hyperlipidemia

ALL of the following

Not reimbursable as an adjunct to LDL-C in the risk assessment and management of cardiovascular disease

ALL of the following

May be reimbursable when a risk-based treatment decision is uncertain after quantitative risk assessment using ACC/AHA PCEs
See hs-CRP-specific criteria for frequency and confirmation (separate criteria group)

hs-CRP reimbursement criteria

Reimbursement stance for hs-CRP testing tied to clinical context:

ALL of the following

hs-CRP testing MAY be reimbursable for individuals for whom a risk-based treatment decision is uncertain after quantitative risk assessment with ACC/AHA Pooled Cohort Equations (PCEs)

ALL of the following

One hs-CRP test for initial screening when used as described above

ALL of the following

If the initial hs-CRP screen is abnormal, a confirmatory hs-CRP test is reimbursable no sooner than two weeks (>=14 days) after the initial test
Document the initial abnormal result

ALL of the following

Procedure and assay coding

Examples of included codes (not exhaustive)CPT

80061	Lipid panel
83700	Lipids, total cholesterol
83695	Apolipoprotein B
86140	C-reactive protein (CRP)

hs-CRP and related assay codesCPT | HCPCS | mixed

84512	C-reactive protein (CRP), quantitative; but payer added
0541U	Proprietary molecular/PLA code added to policy

Lipid panel screening interval

Recommended screening interval (ages 18–79)Every 4 years for individuals ages 18 to 79 years.

Screening interval for increased CVD riskAnnually for individuals at increased risk for cardiovascular disease as defined by 2013 ACC/AHA Pooled Cohort Equations (PCEs).

Annual monitoring for dyslipidemia risk conditionsAnnually for individuals at increased risk of dyslipidemia (eg, obesity/metabolic syndrome, nephrotic syndrome, thyroid disease, pancreatitis, diabetes, chronic kidney disease, Cushing syndrome, pregnancy, cholestatic liver disease, lipid metabolism disorders).

Statin therapy baseline and follow-upBaseline lipid panel before initiating statin therapy; every 4–12 weeks after initiation or change; annually if stable and no medication changes.

Monitoring during long‑term drugsAnnually for individuals on long‑term drug therapy that requires lipid monitoring (eg, isotretinoin, antipsychotics).

Documentation, prior auth, and claims guidance

Documentation Required

Documentation and claims review — submit accurate documentation and provide additional records upon request

Providers are responsible for submitting accurate documentation and claims coded using valid HIPAA-approved code sets; claims are subject to code edit protocols and review against benefit coverage, provider contracts, medical policies, and coding software logic. Upon request, providers must submit any additional documentation to support the claim.

Submit claims using valid HIPAA-approved code combinations and industry-standard coding guidelines (CPT, HCPCS, ICD-10-CM/PCS, UB, NCCI, etc.).
Be prepared to provide additional documentation when requested for claim review or code edit protocols.

Prior Authorization

Prior authorization/documentation guidance for hs-CRP reimbursement

Hs-CRP testing may be reimbursable only for individuals whose treatment decision remains uncertain after quantitative risk assessment with ACC/AHA Pooled Cohort Equations (PCEs); reimbursement is limited to one initial test, a confirmatory test no sooner than two weeks after an abnormal initial result, and annual screening for confirmed elevated hs-CRP. Hs-CRP is not reimbursable for other CVD risk assessments, and conventional CRP is not reimbursable for CVD risk assessment.

Definitions and abbreviations

Simple lipid panel — definition

DefinitionA simple lipid panel is generally composed of total cholesterol, LDL cholesterol, HDL cholesterol, and triglycerides; certain calculated ratios (eg, total/HDL) may also be reported.

Not includedOther tests such as apolipoproteins, lipid particle number or size, and lipoprotein(a) are not considered components of a simple lipid panel.

Use caseSimple lipid panels are the acceptable CVD risk panel for reimbursement under the policy; multi‑marker CVD risk panels are not reimbursable.

PCEs — definition

AcronymPCEs = Pooled Cohort Equations.

Source guideline2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk.

For individuals with confirmed elevated hs-CRP, annual hs-CRP screening may be reimbursable

Document prior confirmed elevation

ALL of the following

ANY of the following
- hs-CRP testing for cardiovascular disease risk assessments not described in the criteria above
- Conventional (non-high-sensitivity) CRP testing for CVD risk assessment

ALL of the following

Policy update: codes 84512 and 0541U were added to the policy; 0423T was removed (see coding section)
Operational timing: confirmatory testing must be performed no sooner than 14 days after the initial abnormal result

hs-CRP confirmatory timing

Confirmatory hs‑CRP timingIf the initial hs‑CRP screen is abnormal, confirmatory hs‑CRP testing is reimbursable no sooner than 2 weeks (≥14 days) after the initial test.

Requirement to document initial abnormal resultConfirmatory testing should be performed after documentation of an initial abnormal hs‑CRP result.

Context of useConfirmatory timing applies when hs‑CRP testing is performed to resolve an uncertain treatment decision after quantitative risk assessment with ACC/AHA PCEs.

hs-CRP screening frequency for confirmed elevation

Frequency for confirmed elevationFor individuals with confirmed elevated hs‑CRP, annual hs‑CRP screening may be reimbursable.

Prerequisite for annual screeningAnnual screening is permitted only after an elevated hs‑CRP has been confirmed by the recommended confirmatory test.

Intended useAnnual hs‑CRP screening applies when prior testing was done to inform a treatment decision that remained uncertain after PCE‑based risk assessment.

One initial hs-CRP test permitted for initial screening when treatment decision is uncertain after PCE risk calculation.
If initial hs-CRP is abnormal, a confirmatory hs-CRP test may be billed no sooner than 14 days after the initial test; document the initial abnormal result.
For individuals with confirmed elevated hs-CRP, annual hs-CRP screening may be reimbursable.
Hs-CRP testing outside these criteria is not reimbursable; conventional CRP is not reimbursable for CVD risk assessment.

PurposePCEs are the risk estimator used to calculate 10‑year risk of atherosclerotic cardiovascular disease (ASCVD) events for treatment decision making.

PCE‑based risk assessment — definition

DefinitionPCE‑based risk assessment is a quantitative risk assessment using the ACC/AHA Pooled Cohort Equations to calculate a patient’s 10‑year risk of cardiovascular disease events.

Role in hs‑CRP useHs‑CRP testing may be considered when a treatment decision remains uncertain after PCE‑based risk estimation.

Risk factors includedPCEs incorporate age, gender, race, smoking, hypertension, diabetes, total cholesterol, and HDL‑/LDL‑cholesterol as key risk inputs.